Hydrocodone Combo Products Come Under FDA Microscope

By Marie PowersStaff Writer

Friday, October 26, 2012

In a two-day meeting that begins this morning, the FDA's Drug Safety and Risk Management (DSaRM) Advisory Committee (adcom) will examine the potential impact of rescheduling hydrocodone combination products  those mixed with other analgesics or as an antitussive  from Schedule III to II, similar to hydrocodone alone.